Descrição

Cell therapies aims to introduce new, healthy cells into a patient’s body, to replace the diseased or missing ones. Manufacturing them involves collecting a specific set of cells from the blood, modifying them to produce a more vigorous attack on a patient’s cancer cells, and then reinjecting them into the patient. The global cell therapy biomanufacturing market is set to increase by US$ 4.4 bilhão de 2022 para 2028, representing a compound annual growth rate (CAGR) de 8.8% durante o período de previsão.

O relatório fornece dados atualizados sobre o tamanho do mercado para o período 2018-2021 e previsão para 2028 covering key market aspects like sales value for cell therapy biomanufacturing. The global cell therapy biomanufacturing market is segmented on the basis of application, and region. On the basis of application, the global cell therapy biomanufacturing market has been segmented into bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, outros. Entre estes, the skeletal muscle repair segment was accounted for the highest revenue generator in 2021. In terms of geography, the global cell therapy biomanufacturing market has been segmented into Asia Pacific, Europa, América do Norte, MEA (Oriente Médio e África), América latina. North America is estimated to account for the largest share of the global cell therapy biomanufacturing market.

The global cell therapy biomanufacturing market is highly competitive. A partir de 2021, the major players in the global cell therapy biomanufacturing market were Bone Therapeutics S.A., Caladrius Biosciences Inc., Iovance Biotherapeutics Inc., Lonza Group AG, Merck KGaA, Novartis AG, Regen BioPharma Inc., Regeneus Ltd., The Bristol-Myers Squibb Company (BMS).

O relatório é um recurso inestimável para empresas e organizações ativas neste setor. It provides a cohesive picture of the cell therapy biomanufacturing market to help drive informed decision making for industry executives, decisores políticos, acadêmico, e analistas.

Escopo do relatório

Aplicativo: bone repair, cancer, cardiovascular diseases, neurological disorders, skeletal muscle repair, outros
Região: Ásia-Pacífico, Europa, América do Norte, MEA (Oriente Médio e África), América latina
Anos considerados: este relatório cobre o período 2018 para 2028

Principais benefícios para as partes interessadas

– Get a comprehensive picture of the global cell therapy biomanufacturing market
– Identifique setores de crescimento e tendências para investimento

Índice

Papel 1. Introdução
– Escopo do estudo
– Período de estudos
– Escopo geográfico
– Metodologia de Pesquisa
Papel 2. Cell therapy biomanufacturing market overview
Papel 3. Market breakdown by application
– Bone repair
– Cancer
– Cardiovascular diseases
– Neurological disorders
– Skeletal muscle repair
– Outros
Papel 4. Market breakdown by region
– Ásia-Pacífico
– Europa
– América do Norte
– MEA (Oriente Médio e África)
– América latina
Papel 5. Principais empresas
– Bone Therapeutics S.A.
– Caladrius Biosciences, Inc..
– Iovance Biotherapeutics, Inc..
– Lonza Group AG
– Merck KGaA
– Novartis AG
– Regen BioPharma, Inc..
– Regeneus Ltd.
– The Bristol-Myers Squibb Company (BMS)
Sobre StrategyHelix
Isenção de responsabilidade